Data were available for more than 550,000 individuals and 51,623 cases of type 2 diabetes. Combined analyses of four independent PCSK9 variants (rs11583680, rs11591147, rs2479409, and rs11206510) scaled to 1 mmol/L lower LDL cholesterol showed associations with increased fasting glucose (0 09 mmol/L, 95% CI 0 02 to 0 15), bodyweight (1 03 kg, 0 24 to 1 82), waist-to-hip ratio (0 006, 0 003 to 0 010), and an odds ratio for type diabetes of 1 29 (1 11 to 1 50). Based on the collected data, we did not identify associations with HbA1c (0 03%, -0 01 to 0 08), fasting insulin (0 00%, -0 06 to 0 07), and BMI (0 11 kg/m2, -0 09 to 0 30). PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins.
The epidemiology of mood disorder, pain and cognitive function
Mental health problems place a large burden on the health service. As life expectancy increases, understanding cognitive decline is increasingly important. Identifying high risk groups enables us to detect problems early and target resources. Understanding the distribution of disease between groups can help elucidate the causes of disease and help identify new methods of prevention and treatment. To examine the frequency, distribution, determinants and outcomes of these conditions, in relation to: demographics, lifestyle, comorbidity and medication
UKB is representative of the general population in terms of age, sex and ethnicity but unrepresentative in terms of lifestyle. Therefore, it is not suitable to determine the overall prevalence of any condition but can, nonetheless, be used to compare the distribution of diseases between sub-groups and therefore determine associations between risk factors and disease frequency and outcome. This project builds on our ongoing study (774) which examines ethnic differences in cardiometabolic disease. We seek to extend the focus to examine other determinants of cardiometabolic disease as well as determinants of mood disorder, cognitive impairment and pain.
Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants.
Low birth weight and features of neuroticism and mood disorder in 83 545 participants of the UK Biobank cohort.
|Lead investigator:||Jill Pell|
|Lead institution:||University of Glasgow|
There are no matching Categories